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SUMMARY 
Objective: Previous studies suggest that androgens have a sexually dimorphic impact on metabolic 
dysfunction. However, the sex-specific link between circulating androgens and risk of type 2 diabetes 
mellitus (T2DM) has not been examined in a large scale, longitudinal cohort, a task we undertook in 
this study.  
Design: A retrospective cohort study in a UK primary care database.  
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Patients: We included men and women with available serum testosterone and sex hormone-binding 
globulin (SHBG) results.  
 
Measurements: We categorized serum concentrations according to clinically relevant cut-off points 
and calculated crude and adjusted T2DM Incidence Rate Ratios (IRRs and aIRRs).  
 
Results: Serum testosterone concentrations were available in 70,541 men and 81,889 women; serum 
SHBG was available in 15,907 men and 42,034 women. In comparison to a reference cohort with 
serum testosterone ≥20nmol/l, men with lower serum testosterone had a significantly increased risk of 
T2DM, with the highest risk in those with serum testosterone <7nmol/l (aIRR 2.71, 95% CI 2.34-
3.14, p<0.001). In women, the risk of T2DM started to increase significantly when serum testosterone 
concentrations exceeded 1.5nmol/l, with the highest risk in women with serum testosterone 
≥3.5nmol/l (aIRR 1.98, 95% CI 1.55-2.52, p<0.001). These observations were verified in a continuous 
rather than categorized analysis. The risk of T2DM increased in men and women with serum SHBG 
<40nmol/L and <50nmol/L, respectively.  
 
Conclusions/Interpretation: In this longitudinal study, we found sexually dimorphic associations 
between serum testosterone and risk of incident T2DM. Androgen deficiency and excess should be 
considered important risk factors for diabetes in men and women, respectively.  
 
Key words: Testosterone, androgens, hypogonadism, sex hormone-binding globulin, diabetes, 
metabolic diseases, population health  
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INTRODUCTION 
Sex differences are critical in the epidemiology and pathophysiology of metabolic disease, 
with an increased incidence of type 2 diabetes mellitus (T2DM) and cardiovascular disease in men 
1
. 
Sex hormones such as androgens may mediate these differences, but the association between 
androgens and metabolic dysfunction is complex and sex-specific 
2
. Androgen excess has recently 
been identified as an independent risk factor for non-alcoholic fatty liver disease (NAFLD) in women 
3
, and promotes lipid accumulation in female adipose tissue as well as systemic lipotoxicity 
4
. Female-
to-male gender reassignment patients undergoing androgen therapy develop dyslipidemia and 
abnormal body composition 
5,6
. Mirroring this, the adverse metabolic phenotype of male androgen 
deficiency bears a striking similarity to that of female androgen excess; lower testosterone levels in 
men are associated with impaired glucose homeostasis, hepatic steatosis and coronary artery disease 
7-
9
. A number of meta-analyses support a sex-specific relationship between androgens and the risk of 
metabolic dysfunction, and suggest that low circulating sex hormone-binding globulin (SHBG) 
concentrations may be metabolically harmful in both sexes 
9,10
.  
Delineating an independent role for androgens in the pathogenesis of T2DM is confounded by 
changes in body composition, body mass index and lean mass observed in disorders of androgen 
excess and deficiency 
11
. Against the background of a global epidemic of T2DM 
12
, there is an urgent 
health need to understand the sexually dimorphic role played by androgens in the pathogenesis of 
hyperglycemia. The shared constellation of risk factors observed in women with androgen excess and 
men with androgen deficiency suggests that circulating androgen concentrations common to both 
disorders may be metabolically disadvantageous 
2
. To our knowledge, however, no large longitudinal 
studies have specifically examined the association between circulating androgen exposure per se and 
risk of T2DM in a sex-specific context.   
The aim of this study was to investigate the independent sex-specific association between 
serum testosterone concentrations and the risk of hyperglycaemia in men and women by undertaking 
a retrospective cohort study in a large and diverse UK population base.   
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MATERIALS AND METHODS 
Database 
A large primary care database in the UK with contribution from over 700 general practices 
(14 million patients) was utilized for this study. Data from practices that use VISION Electronic 
Medical Record (EMR) are gathered, anonymized and released for research purpose 
13
. The resulting 
database, The Health Improvement Network (THIN) database holds data on demographic 
characteristics, clinical diagnosis, physical measurement, laboratory results and prescriptions. The 
THIN database is broadly representative of the UK population structure 
14
 and has been utilized for 
numerous epidemiological studies, including studies on T2DM 
15,16
 and sex hormones 
3,17,18
. 
 
Testosterone and Sex Hormone Binding Globulin (SHBG) measurements  
Men or women over the age of 16 who had a measurement of the serum concentration of 
testosterone or SHBG between 1
st
 of Jan 2000 and 15
th
 of May 2016 were eligible to take part in the 
study. Common clinical indications for these measurements include suspected polycystic ovary 
syndrome (PCOS) in women, infertility investigations in both sexes and erectile dysfunction in men 
19,20
 . Where multiple measurements were available in one individual, the first measurement was 
utilized. Patients with the outcome of interest (T2DM) preceding the index date were excluded from 
the study. 
Exposure categories 
To explore non-linear relationships, establish gradient increase and assess risk within the 
normal range, measurements were categorized by applying clinically relevant cut-off points for serum 
concentrations (nmol/L)
3
. For women, testosterone was grouped as <1.0nmol/L (reference group), 
1.0-1.49, 1.5- 1.99, 2.0-2.49, 2.5-2.99, 3.0-3.49 and >3.5 nmol/L. For men, the groups were as 
follows: <7, 7-9.9, 10.0-14.9, 15-19.9, >20.0nmol/L (reference group) nmol/L. For both sexes, SHBG 
was categorized as >60.0nmol/L (reference group), 50.0-59.9, 40.0-49.9, 30.0-39.9, 20.0-29.9 and < 
20 nmol/L. Exposures were also treated as continuous variables and risk of T2DM assessed.  
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
Follow-up period 
The date of measurement of testosterone or SHBG served as the index date. Each participant 
was followed-up from the index date until the exit date. Exit date was defined as the earliest of the 
following dates: outcome (diagnosis of T2DM), study end, death or the date they left the general 
practice or the general practice stopped contributing to the database.  
 
 Outcome and covariates 
A clinical diagnosis of T2DM by the general practitioner was the outcome of interest. In the 
UK, the Quality Outcome Framework (QOF) in general practices ensures high quality data on 
important comorbidities such as cardiovascular disease, hypertension and T2DM 
21
 . Within the 
database, diagnostic codes for T2DM were identified based on Read codes, a hierarchical coding 
system to record signs, symptoms, procedures and diagnosis in primary care 
3
. Covariates that are 
independent predictors of T2DM other than the exposure of interest were selected on the basis of 
biological plausibility and previous literature 
22
. These included age, body mass index (BMI), 
Townsend deprivation score and smoking status. 
Statistical analysis 
Baseline data of each category in the serum testosterone and SHBG cohorts was reported 
separately for men and women as mean (standard deviation) or median (interquartile range [IQR]) as 
appropriate for continuous variables and as proportions for categorical variables. Crude Incidence 
Rate Ratio (IRR) and adjusted Incidence Rate Ratio (aIRR) were calculated by applying Poisson 
regression offsetting for the person years of follow-up. Covariates adjusted for in the model were age, 
BMI, Townsend quintiles and smoking status. In women, an additional model included polycystic 
ovary syndrome (PCOS) as a covariate to explore if the risk of T2DM in women was independent of a 
diagnosis of PCOS. In an additional sensitivity analysis, when adjusting for PCOS. we accepted the 
presence of hirsutism and anovulation as indicative of PCOS given that the diagnosis is underreported 
in primary care.  
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Where missing data existed (BMI, Townsend or smoking), we created a separate category so 
that all available data is utilized in the analysis. BMI was categorized as per WHO recommendation 
into <25.0kg/m
2
, 25-29.0kg/m
2
 and >30kg/m
2
. All analyses were performed in STATA 14.0. 
 
Subgroup analysis 
In women, we performed stratified analysis by age (<50 years and 50 years and above) to 
explore if the association was similar before and after the average age of menopause. A similar age-
stratified analysis was also carried out in men. In addition to this, in those patients with simultaneous 
measurements of testosterone and SHBG, a free androgen index (FAI) was calculated 
[(Tx100)/SHBG], and risk of T2DM calculated to control for the confounding effect of low SHBG 
levels.  
 
Ethical Approval 
This study used routinely collected, anonymised primary care data. Patients were not involved 
in the study, and therefore no consent was required. Research using THIN data was approved by the 
NHS South-East Multicentre Research Ethics Committee in 2003, with the condition that studies 
undergo independent scientific review 
23
. Approval for this analysis was obtained from the Scientific 
Review Committee for the use of THIN data in January 2018 (SRC reference number 17THIN106). 
 
RESULTS 
Characteristics of the cohorts with serum testosterone and SHBG measurements 
A total of 152,430 participants in the cohort with available serum testosterone measurement 
results (testosterone cohort; 70,541 men and 81,889 women) and a total of 57,942 participants 
(15,907 men and 42,035 women) in the SHBG cohort, both derived from the THIN database, met the 
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inclusion criteria and were included in the current study. Median follow-up in the testosterone cohort 
was 3.3 years (IQR:1.5-6.1) in men and 3.2 (IQR:1.3-6.2) years in women. In the SHBG cohort, 
median follow-up was 2.8 (1.3-4.9) years in men and 2.8 (1.2-5.4) in women. The mean age for 
men was 51.6 (SD 14.8) years in the testosterone cohort and 51.7 (SD 16.0) years in the SHBG 
cohort. For women, mean age was 33.2 (SD 10.9) years in the testosterone cohort and 32.1 (SD 
10.6) years in in the SHBG cohort. In total, 40,464 (57.4%) men in the testosterone cohort and 9,795 
(61.6%) men in the SHBG cohort were overweight or obese (BMI ≥25kg/m2). Among women, 36,640 
(44.7 %) were obese or overweight in the testosterone cohort and 19,270 (45.8%) in the SHBG 
cohort. Approximately 21% of men and 22% of women were smokers across both testosterone and 
SHBG cohorts (Table 1). A diagnosis of PCOS was only documented in 6.3% (N=5,136) and 7.9% 
(N=3,303) of the female testosterone and SHBG cohorts, respectively. However, clinical features 
suggestive of PCOS, anovulation and clinical evidence of hirsutism, were documented in 25.8% and 
11.2% of the female testosterone cohort, respectively, and in 26.9% and 12.1% of the female SHBG 
cohort, respectively.  
Biochemical evidence of male androgen deficiency (serum testosterone <7nmol/L) was 
observed in 5,862 men (8.3%). Biochemical evidence of female androgen excess (serum testosterone 
>2nmol/L) was observed in 20,565 women (25.1%); of those, 2,481 women (3.0%) had severe 
androgen excess (serum testosterone 3.5 nmol/L). Serum SHBG concentrations <20nmol/L were 
observed in 2,517 (15.8%) men and 3,733 (8.9 %) women (Suppl. Tables 1-4).   
 
Association between sex hormones and T2DM risk in men  
Among 70,541 men with serum testosterone measurements, 3,156 developed T2DM during 
the follow-up period. As expected, increasing age, overweight/obesity, smoking and higher social 
deprivation conferred an increased risk for T2DM (Suppl. Tables 5 and 6). 
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After adjusting for age, BMI, Townsend index and smoking status, aIRR for T2DM in men 
increased with decreasing categories of serum testosterone concentrations, most notably a 271% 
higher risk of developing T2DM in those with testosterone levels <7nmol/L, compared to the 
reference category of 20nmol/L (aIRR 2.71, 95% CI 2.34-3.14, p<0.001, Table 2). However, the 
risk of T2DM increased even within the normal male testosterone range (15-19.99 nmol/L, aIRR 1.29, 
95% CI 1.13-1.47, p<0.001; 10-14.99 nmol/L, aIRR 1.90, 95% CI 1.68-2.15, p<0.001, Table 2 & 
Figure 1A+B).   
In the SHBG cohort, among 15,907 men studied, there were 708 cases of incident T2DM 
during the follow-up period. After adjusting for age, BMI, Townsend index and smoking status, the 
risk of T2DM increased in men with SHBG levels <40nmol/L; aIRR of incident T2DM increased 
across categories of decreasing SHBG concentrations as compared to the reference category 
(≥60nmol/L) and the risk was more than 5-fold higher in the group with SHBG <20nmol/L (aIRR 
5.74, 95% CI 3.72-8.87, Table 2 & Figure 1C+D).  
 
Association between sex hormones and T2D risk in women  
Among 81,889 women with serum testosterone measurements, 1,282 developed T2DM 
during the follow-up period. After adjusting for age, BMI, Townsend index and smoking status, 
T2DM aIRR tended to be higher with increasing serum testosterone levels. The risk increased 
significantly for serum testosterone levels >1.5 nmol/L, as compared to reference category 
(<1nmol/L), and continued to increase across each category of serum testosterone concentrations 
thereafter, with a two-fold increase in risk observed in women with serum testosterone ≥3.5 nmol/L 
(aIRR 1.98, 95% CI 1.55-2.52, p<0.001, Table 2 & Figure 2A+B). Further adjustment for a 
diagnosis of PCOS or clinical features of suspected PCOS (hirsutism or anovulation) did not 
substantially change results (aIRR in subgroup of women with testosterone levels >3.5 nmol/L = 1.89, 
95% CI 1.48-2.42, p<0.001 and 1.76, 95% CI 1.38-2.25, p<0.001 respectively, Suppl. Table 7). 
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 In the SHBG cohort, among 42,034 women studied, there were 597 cases of incident T2DM 
during the follow-up period. The risk of incident T2DM increased with each category of decreasing 
SHBG concentration. Women with serum SHBG concentrations <20nmol/L had a 9-fold higher risk 
of developing T2DM compared to the reference category of ≥60nmol/L (aIRR 9.23, 95% CI 6.61-
12.88, p<0.001), after adjustment for age, BMI, Townsend index and smoking status (Table 2 & 
Figure 2C+D). Additional adjustment for a diagnosis of PCOS and clinical features of suspected 
PCOS did not alter the risk of T2DM (aIRR 9.13, 95% CI 6.53-12.75, p<0.001 and aIRR 8.88, 95% 
CI 6.36-12.42, p<0.001 respectively, Suppl. Table 8).  
 
Analysis of sex hormones as a continuous variable  
In men, for every nmol/L decrease in testosterone, the risk of T2DM increased by 5% (aIRR 
1.05, 95% CI 1.04-1.06, p<0.001). In women, for every nmol/L increase in testosterone, the risk of 
T2DM increased by 10% (aIRR 1.10, 95% CI 1.06-1.14, p<0.001). In the analysis of SHBG, for every 
nmol/L decrease in SHBG the risk of T2DM increased by 3% in both men and women (aIRR 1.03, 
95% CI 1.03-1.04, p<0.001, in both sexes). 
 
Free androgen index and risk of T2DM 
Only 40% women (n=34,578) and 16% of men (n=12,178) had undergone a simultaneous 
measurement of serum SHBG and testosterone. Using these to calculate the free androgen index 
(FAI), we found that FAI was positively associated with risk of T2DM in women (aIRR 1.03, 95% CI 
1.02-1.04, p<0.001), but not in men (aIRR 1.00, 95% CI 0.997-1.004, p=0.789). 
Subgroup analyses  
Subgroup analysis stratified by age (<50 and 50 years) did not alter the observed 
associations. In both age groups, a gradient increase in risk of T2DM was observed with increasing 
testosterone concentrations in women and decreasing testosterone concentrations in men (Suppl. Fig 
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1 and Suppl. Tables 9-12). Increased aIRRs for T2DM were noted with lower concentrations of 
SHBG in both age groups in men and women (Suppl. Fig 2 and Suppl. Tables 13-16).  
 
DISCUSSION 
In this large retrospective cohort study, we have demonstrated that androgens confer an 
independent sex-specific effect on the risk of incident T2DM. To our knowledge, this is the largest 
study, and the first longitudinal analysis, to address the impact of serum testosterone on risk of 
development of T2DM in both men and women. In the female cohort, aIRRs for T2DM increased 
significantly once serum testosterone concentrations increased above 1.5nmo/L; even those with 
circulating testosterone levels between 1.5 and 1.99nmol/L, conventionally considered within the 
normal physiological range for women, already had a 23% increased risk of T2DM compared to the 
reference group. Perhaps even more surprisingly, once male serum testosterone concentrations 
dropped below 20nmol/L, the risk of T2DM began to increase; men with circulating concentrations 
between 15 and 19.99nmol/L, i.e. within the normal physiological male range, had a 28% increased 
risk of T2DM over the study period. Reduced SHBG concentrations in both sexes, but particularly in 
women, also potently increased the risk of T2DM. This finding is in agreement with observations 
from some previous studies, which demonstrated a stronger inverse association between SHBG levels 
and risk of T2DM in women compared to men 
10,24
. This inverse relationship with T2DM appears to 
be particularly strong in postmenopausal women 
25
. A 2011 meta-analysis, however, found that higher 
SHBG levels were equally associated with a reduced risk of metabolic syndrome in both sexes 
26
.  
A systematic review and meta-analysis, which included a total of 3825 men and 4795 women 
in 36 cross-sectional studies, as well as 368 cases from 7 prospective study populations, previously 
demonstrated that increased serum testosterone was associated with a 60% higher risk of T2DM in 
women; higher testosterone levels in men reduced the risk of T2DM by 42% 
10
. Goodman-Gruen et al 
also observed sex differences in the association between serum androgens and glucose tolerance status 
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in an older community cohort of 775 men and 633 women above the age of 55 
27
. Men with impaired 
fasting glucose, impaired glucose tolerance and T2DM had significantly lower levels of serum 
testosterone, while women with T2DM had significantly higher levels of bioavailable testosterone, 
independent of total body fat, fat distribution, physical activity and smoking.  However, our study is 
the only longitudinal retrospective analysis to comprehensively evaluate these associations.  
A number of key insights into the role of androgen excess in the development of metabolic 
dysfunction is provided by studies in women with polycystic ovary syndrome (PCOS), a disorder 
affecting up to 10% of the female population and primarily defined by the presence of 
hyperandrogenism and ovulatory dysfunction 
28
. We have recently demonstrated that lean women 
with PCOS have an almost two-fold increased risk of NAFLD, a hepatic manifestation of metabolic 
dysfunction, and that androgen excess is an independent mediator of this increased risk 
3
. Androgen-
mediated adipose tissue lipotoxicity may contribute to this increase in NAFLD risk 
4,29
. PCOS women 
are at significantly increased risk of impaired glucose tolerance and T2DM at a young age, 
irrespective of body weight 
30
. A recent large Danish population register study concluded that the risk 
of T2DM was four-fold higher for women with PCOS, and diagnosed 4 years earlier, compared to 
women in the background population 
31
.  
Male androgen deficiency occurs as a consequence of primary testicular pathology, 
hypothalamic-pituitary disorders, obesity or as part of the ageing process in older men 
32,33
. 
Additionally, iatrogenic hypogonadism due to androgen deprivation therapy is observed in men with 
prostate cancer 
34
. Whilst the relationship between obesity and hypogonadism in men is complex and 
bidirectional 
35
, data from male cohorts treated with short term androgen deprivation therapy show 
that hypogonadism directly induces metabolically deleterious changes in body composition, with 
increases in weight and in percentage fat body mass 
36
. However, studies of androgen deprivation 
therapy, which result in significant hypogonadism, are not an ideal model to compare to the relatively 
modest reductions in testosterone observed in community-dwelling older men. The results of our 
study are particularly surprising, given that an increased risk of T2DM was apparent at circulating 
testosterone concentrations considered physiologically normal, but below the reference group of 
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20nmol/L, independent of age, obesity and other potential confounding factors. However, our results 
do not imply endorsement of testosterone pharmacotherapy to restore circulating testosterone levels 
above 20nmol/L in otherwise healthy men. Studies investigating a potential beneficial impact of 
androgen therapy on metabolic outcomes in men with testosterone concentrations in the low or low-
normal range have shown at best conflicting results. A recent double-blind placebo-controlled trial of 
testosterone treatment in 788 older men showed no impact on serum glucose or HbA1C 
37
; another 
study showed no change in insulin sensitivity after 36 months of treatment in 308 community-
dwelling men 
38
. The 2018 Endocrine Society Clinical Practice Guideline on testosterone therapy in 
men with hypogonadism no longer recommend screening men with T2DM for low serum 
testosterone, and advise against using testosterone therapy to improve glycaemic control 
39
.  
Low circulating SHBG has been consistently identified as a surrogate marker for T2DM in 
both sexes in a number of smaller studies and meta-analyses 
10,40,41
, and our study supports these 
observations. In a meta-analysis of 13 population-based studies with 1,912 incident cases of T2DM, 
low SHBG was associated with increased risk of T2DM in women, irrespective of menopausal status 
40
. SHBG levels are typically higher in women, and our data confirm that reduced circulating 
concentrations are associated with a higher risk of T2DM than that observed in men. SHBG is a 
critical mediator of the association between sex steroids and metabolic dysfunction. The majority of 
circulating testosterone is bound to SHBG, such that only the unbound or ‘free’ fraction is capable of 
exerting effects in target tissues 
42
. Therefore, reduced SHBG levels in women are a surrogate marker 
of increased circulating active androgens. Insulin is a potent regulator of hepatic SHBG output, which 
is suppressed in the context of hyperinsulinemia, leading to reduced SHBG, and therefore increased 
free androgens, in insulin resistant states such as PCOS in women 
43
. It is unlikely, however, that 
SHBG independently plays a causal role in the pathophysiology of metabolic diseases such as T2DM. 
Low SHBG and testosterone levels in men are likely to be mediated by obesity in a population already 
at increased risk 
44
. We found that FAI in men did not have a negative linear association with T2DM 
risk, indicating that low SHBG rather than testosterone is the predominantly associated with 
metabolic risk in men. This supports the observations of Bhasin 
45
, but conflicts with those of Haring 
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et al, who found that declining testosterone rather than SHBG levels were the main driver of 
metabolic syndrome in a large German cohort 
46
. It is important to note that FAI must be interpreted 
with caution in both men and women, and is particularly inaccurate in women when the SHBG 
concentration falls below 30nmol/l 
47
.  
This study has a number of important limitations, not least its retrospective nature. Detailed 
clinical phenotyping in studies of this type are not possible. There are also no detailed data available 
on laboratory assays used to measure serum testosterone. This is not of particular concern in men, as 
physiologically higher testosterone concentrations do not represent a challenge for quantification by 
either radioimmunoassay (RIA) or tandem mass spectrometry techniques. In women, however, where 
low circulating concentrations pose significant analytical and quantification difficulties for standard 
RIAs, the consensus is that today measurements should be performed by liquid chromatography-
tandem mass spectrometry to improve quantification and avoid cross reactivity 
48
. Furthermore, we 
have no information on the time of day blood sampling for serum testosterone took place; in men, 
Endocrine Society guidelines emphasize that morning samples are crucial to accurately diagnose 
hypogonadism 
49
. Lastly, we must assume that testosterone data were obtained from men and women 
with a clinical indication for serum measurement; this introduces a potential bias by indication. 
However, we believe that these limitations are ameliorated by the large patient numbers and the clear 
and potent gradient towards sex-specific T2DM risk in the study population.  
In conclusion, in the largest retrospective longitudinal study of its kind, we have demonstrated 
evidence of a sexually dimorphic role for androgens in mediating the risk of T2DM. Reduced SHBG 
levels in both sexes, but particularly in women, significantly increase the risk of T2DM. These data 
further define androgens as a novel metabolic risk factor in men and women, but potential 
mechanisms underpinning these observations remain to be clarified. We suggest that women with 
androgen excess and men with androgen deficiency should be systematically screened for T2DM. 
Future studies will be required to show if reducing androgens in women, and increasing androgens in 
men, will improve overall metabolic health and risk of progression to overt T2DM.  
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FIGURE LEGENDS 
Figure 1: Risk of incident type 2 diabetes (T2DM) according to serum testosterone and sex hormone-
binding globulin (SHBG) concentration categories in men. (A) Adjusted Incidence Rate Ratios 
(aIRRs) for diabetes in 70,541 men with serum testosterone measurements. (B) Distribution of 70,541 
men across each quintile of serum testosterone concentration. (C) aIRRs for serum SHBG 
concentrations for incident diabetes in 15,907 men. (D) Distribution of 15,907 men across each 
category of serum SHBG concentration.  
 
Figure 2: Risk of incident type 2 diabetes (T2DM) according to serum testosterone and sex hormone-
binding globulin (SHBG) concentrations in women. (A) Adjusted Incidence Rate Ratios (aIRRs) for 
incident diabetes in 81,889 women with serum testosterone measurements. (B) Distribution of 81,889 
women across each category of serum testosterone concentration. (C) aIRRs for serum SHBG 
concentrations for incident diabetes in 42,034 women with serum SHBG measurements. (D) 
Distribution of 42,034 women across each category of serum SHBG concentration.
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Table 1: Baseline characteristics of the testosterone and SHBG cohorts stratified by sex  
Characteristics 
Men                                                                     Women                    
Serum testosterone Serum SHBG Serum testosterone Serum SHBG 
Population                             
n (%) 70,541 (46.28) 15,907 (27.45) 81,889 (53.72) 42,034 (72.55) 
Age (years)                    
mean (SD) 51.6 (14.8) 51.7 (16.0) 33.2 (10.9) 32.1 (10.6) 
Townsend index n (%) 
 
   
1 (least deprived) 20,017 (28.38) 3,997 (25.13) 18,470 (22.55) 8,753 (20.82) 
2 
15,481 (21.95) 3,427 (21.54) 15,688 (19.16) 7,688 (18.29) 
3 13,687 (19.40) 3,033 (19.07) 17,043 (20.81) 8,681 (20.65) 
4 10,997 (15.59) 2,565 (16.12) 15,295 (18.68) 8,155 (19.40) 
5 (most deprived) 7,374 (10.45) 2,186 (13.74) 10,269 (12.54) 5,955 (14.17) 
Missing or implausible data 
2,985 (4.23) 699 (4.39) 5,124 (6.26) 2,802 (6.67) 
BMI (kg/m
2
) categorised  
n (%)  
  
 
<25 19,195 (27.21) 3,995 (25.11) 32,519 (39.71) 15,975 (38.00) 
25-30 25,962 (36.80) 5,817 (36.57) 16,849 (20.58) 8,445 (20.09) 
>30 14,502 (20.56) 3,978 (25.01) 19,791 (24.17) 10,825 (25.75) 
Missing or implausible data 
10,882 (15.43) 2,117 (13.31) 12,730 (15.55) 6,789 (16.15) 
Smoking status  
n (%)  
  
 
Non-smokers 53,311 (75.57) 12,264 (77.10) 61,288 (74.84) 31,557 (75.07) 
Smokers 15,325 (21.72) 3,377 (21.23) 18,020 (22.01) 9,312 (22.15) 
Missing or implausible data 
1,905 (2.70) 266 (1.67) 2,581 (3.15) 1,165 (2.77) 
Confounding conditions      
PCOS   5,136 (6.27) 3,303 (7.86) 
Anovulation   21,148 (25.83) 11,288 (26.85) 
Hirsutism   9,133 (11.15) 5,064 (12.05) 
Follow-up in years  
median (IQR) 
3.3 (1.5 – 6.1) 2.8 (1.3 – 4.9) 3.2 (1.3 – 6.2) 2.8 (1.2 – 5.4) 
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Table 2. Risk of incident T2DM according to the category of serum testosterone and SHBG at 
baseline 
 
  
IRR (95% CI); p-value 
Adjusted
1
 Adjusted
2
 Adjusted
3
 Adjusted
4
 
MEN 
Serum testosterone concentration categories (nmol/L) 
< 7 
3.82 (3.31-4.41); 
p<0.001 
2.60 (2.25-3.00); 
p<0.001 
2.71 (2.34-3.14); 
p<0.001 
 
7 - 9.99 
3.70 (3.24-4.22); 
p<0.001 
2.46 (2.15-2.81); 
p<0.001 
2.57 (2.24-2.94); 
p<0.001 
 
10 - 14.99 
2.40 (2.13-2.71); 
p<0.001 
1.83 (1.62-2.06); 
p<0.001 
1.90 (1.68-2.15); 
p<0.001 
 
15 - 19.99 
1.45 (1.27-1.66); 
p<0.001 
1.25 (1.09-1.43); 
p=0.001 
1.29 (1.13-1.47); 
p<0.001 
 
> 20 Ref Ref Ref 
 
Serum SHBG concentration categories (nmol/L) 
<20 
8.23 (5.37-12.63); 
p<0.001 
5.00 (3.24-7.71); 
p<0.001 
5.74 (3.72-8.87); 
p<0.001 
 
20 - 29.99 
4.30 (2.83-6.53); 
p<0.001 
2.92 (1.91-4.44); 
p<0.001 
3.20 (2.09-4.87); 
p<0.001 
 
30 - 39.99 
3.33 (2.19-5.08); 
p<0.001 
2.45 (1.60-3.74); 
p<0.001 
2.61 (1.71-3.99); 
p<0.001 
 
40 - 49.99 
1.56 (0.98-2.50); 
p=0.063 
1.28 (0.80-2.06); 
p=0.298 
1.36 (0.85-2.17); 
p=0.207 
 
50 - 59.99 
1.07 (0.61-1.87); 
p=0.825 
0.88 (0.50-1.54); 
p=0.654 
0.91 (0.52-1.60); 
p=0.748 
 
≥60 Ref Ref Ref  
WOMEN 
Serum testosterone concentration categories (nmol/L) 
< 1 Ref Ref Ref Ref 
1.0 - 1.49 
1.21 (1.02-1.43); 
p=0.030 
1.12 (0.95-1.33); 
p=0.184 
1.12 (0.94-1.32); 
p=0.204 
1.11 (0.94-1.32); 
p=0.213 
1.5 - 1.99 
1.45 (1.23-1.70); 
p<0.001 
1.26 (1.07-1.48); 
p=0.005 
1.23 (1.05-1.45); 
p=0.011 
1.23 (1.04-1.44); 
p=0.013 
2.0 - 2.49 
1.70 (1.42-2.04); 
p<0.001 
1.34 (1.12-1.61); 
p=0.002 
1.30 (1.08-1.56); 
p=0.005 
1.28 (1.07-1.54); 
p=0.008 
2.5 - 2.99 
2.07 (1.67-2.58); 
p<0.001 
1.59 (1.27-1.97); 
p<0.001 
1.53 (1.23-1.90); 
p<0.001 
1.50 (1.20-1.87); 
p<0.001 
3.0 - 3.49 
2.51 (1.90-3.32); 
p<0.001 
1.74 (1.31-2.30); 
p<0.001 
1.68 (1.27-2.23); 
p<0.001 
1.62 (1.22-2.15); 
p=0.001 
≥ 3.5 
3.00 (2.36-3.82); 
p<0.001 
2.09 (1.64-2.67); 
p<0.001 
1.98 (1.55-2.52); 
p<0.001 
1.89 (1.48-2.42); 
P<0.001 
Serum SHBG concentration categories (nmol/L) 
<20 
19.76 (14.36-
27.21); p<0.001 
8.96 (6.42-
12.50); p<0.001 
9.23 (6.61-
12.88); p<0.001 
9.13 (6.53-
12.75); p<0.001 
20 - 29.99 
8.66 (6.29-11.93); 
p<0.001 
4.45 (3.20-6.19); 
p<0.001 
4.48 (3.22-6.24); 
p<0.001 
4.44 (3.19-6.18); 
p<0.001 
30 - 39.99 
4.66 (3.31-6.57); 
p<0.001 
2.69 (1.90-3.82); 
p<0.001 
2.70 (1.91-3.84); 
p<0.001 
2.69 (1.90-3.82); 
p<0.001 
40 - 49.99 2.99 (2.04-4.38); 2.05 (1.40-3.02); 2.08 (1.41-3.05); 2.07 (1.41-3.05); 
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p<0.001 p<0.001 p<0.001 p<0.001 
50 - 59.99 
1.64 (1.02-2.64); 
p=0.043 
1.29 (0.80-2.08); 
p=0.295 
1.29 (0.80-2.07); 
p=0.304 
1.29 (0.80-2.08); 
p=0.301 
≥60 Ref Ref Ref Ref 
 
1
 Adjusted for age,  
2
 Adjusted for age, BMI,  
3
 Adjusted for age, BMI, Townsend index, smoking status 
4
 Adjusted for age, BMI, Townsend index, smoking status, PCOS 
 
Abbreviations: IRR, incidence rate ratio; SHBG, sex hormone-binding globulin; T2DM, type 2 
diabetes mellitus 
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